Trial Profile
Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms ELEVATE
- Sponsors GlaxoSmithKline; GSK
- 07 Oct 2014 New trial record